Jaguar Health Inc. (JAGX), a commercial-stage pharmaceutical company, announced on Monday a planned launch of Neonorm Dog, an extension of the Neonorm franchise that exclusively caters to dog health.
The company expects to provide dog owners with access to plant-based, non-prescription products to support normal stool formation, gut hydration, and bowel health. The products are largely derived from the extract of the Croton lecheri tree. The platform will be made available through online or retail animal health channels.
Neonorm was established to provide non-prescription healthcare to companion animals and currently consists of the Neonorm Foal and Neonorm Calf subsidiaries.
Previously, Jaguar received a conditional approval from the FDA for Canalevia CA-1 for treating chemotherapy-induced diarrhea in dogs.
JAGX is currently trading at $3.04, down 49.01%
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.